Log In
Print
BCIQ
Print
Print this Print this
 

SIRPalphaFc (formerly TTI-621)

  Manage Alerts
Collapse Summary General Information
Company Trillium Therapeutics Inc.
DescriptionSignal regulatory protein alpha (SIRPA) fused to immunoglobulin Fc region
Molecular Target CD47
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2.9M

$1.2M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today